(Reuters) – The University of Oxford expects efficacy data on a study of its COVID-19 vaccine against the UK variant of the coronavirus by next week, a representative said on Wednesday at a virtual meeting of a U.S. CDC advisory panel.
“Since the middle of December, that (UK) variant has been dominant and spread so rapidly. And so, we should be able to put together an analysis on efficacy against that probably by next week,” said Andrew Pollard, director of the Oxford Vaccine Group and chief investigator of the trials.
Oxford University has developed the vaccine along with AstraZeneca.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty)
